Dr Kathy Miller's preview of SABCS 2014 spotlights key data in triple-negative, HER2+, and local-regional disease as well as the much-anticipated results from the SOFT trial.
Dr Kathy Miller's preview of SABCS 2014 spotlights key data in triple-negative, HER2+, and local-regional disease as well as the much-anticipated results from the SOFT trial.